NCT01119924

A Clinical Study for Assessment of the Efficacy and Safety of Mirtazapine (Smilon) in Depression Patients With Pain

Phase IV Study for Evaluation the Efficacy and Safety of Mirtazapine (Smilon) in Depression Patients With Pain

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Nang Kuang Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the Efficacy and Safety of Smilon® in the Depression Patients with pain. Eligible patients will be randomly assigned to 1 of 2 arms, either Smilon® or placebo, and will receive the treatment for 8 weeks in this study.

Conditions

• Depression
• Pain

Interventions

Type	Name	Description
DRUG	Smilon®	Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
DRUG	Placebo	Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks

Timeline

• Start date: 2009-12-01
• Primary completion: 2010-08-01
• Completion: 2010-11-01
• First posted: 2010-05-10
• Last updated: 2011-06-09

Locations

1 site across 1 country: Taiwan